Molecular interactions between NAFLD and xenobiotic metabolism

• Main Authors: Adviti eNaik, Aleš eBelič, Ulrich M Zanger, Damjana eRozman
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2013-01-01
• Series: Frontiers in Genetics
• Subjects: Nuclear Receptors; transporters.; NAFLD; xenobiotic metabolism; phase I and II metabolism
• Online Access: http://journal.frontiersin.org/Journal/10.3389/fgene.2013.00002/full

Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, is a complex multifactorial disease characterised by metabolic deregulations that include accumulation of lipids in the liver, lipotoxicity and insulin resistance. The progression of NAFLD to NASH and cirrhosis, and ultimately to carcinomas, is governed by interplay of pro-inflammatory pathways, oxidative stress, as well as fibrogenic and apoptotic cues. As the liver is the major organ of biotransformation, deregulations in hepatic signalling pathways have effects on both, xenobiotic and endobiotic metabolism. Several major nuclear receptors involved in the transcription and regulation of phase I and II drug metabolizing enzymes and transporters also have endobiotic ligands including several lipids. Hence, hepatic lipid accumulation in steatosis and NAFLD, which leads to deregulated activation patterns of nuclear receptors, may result in altered drug metabolism capacity in NAFLD patients. On the other hand, genetic and association studies have indicated that a malfunction in drug metabolism can affect the prevalence and severity of NAFLD. This review focuses on the complex interplay between NAFLD pathogenesis and drug metabolism. A better understanding of these relationships is a prerequisite for developing improved drug dosing algorithms for the pharmacotherapy of patients with different stages of NAFLD.